Business
New Patent Allowance
New Patent Allowance.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n\nSareum Holdings PLC\n(\"Sareum\" or the \"Company\")\nNew Patent Allowance\nCambridge, UK, 15 March 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, today announces that the European Patent Office has issued a Notice of Allowance for a patent relating to SDC‐1801, the Company's lead TYK2/JAK1 kinase inhibitor, currently in clinical development in Australia.\nThe newly approved European patent application, EP3864009, safeguards SDC‐1801, its medical applications particularly in the treatment of autoimmune diseases, and certain methods of synthesis.\nThis follows approvals in 2023 by the China National Intellectual Property Administration, and the Japan Patent Office for the same protections.\nPatent applications in the US (US2021387981) and other territories are still under review.\nThe Company expects that the patent will be granted in the near future, subject to certain formalities being completed.\nDr John Reader, Sareum's Chief Scientific Officer, commented: \"This new patent allows us to enhance our intellectual property portfolio in a crucial market. Our Phase 1a trial for SDC-1801 in Australia is progressing smoothly, with the Single Ascending Dose (SAD) and Food Effect study revealing no significant adverse events. This progress highlights the potential of SDC-1801 to achieve therapeutic drug levels in the bloodstream through once-daily oral dosing.\"\n- Ends -\nFor further information, please contact: \n\n\n\n\nSareum Holdings plc\nTim Mitchell, CEO\nLauren Williams, Head of Investor Relations\n \n\n\n \n01223 497700\[email protected]\n \n\n\n\n\nStrand Hanson Limited (Nominated Adviser)\nJames Dance / James Bellman\n \n\n\n \n020 7409 3494\n\n\n\n\nPeel Hunt LLP (Joint Corporate Broker)\nJames Steel / Patrick Birkholm\n \n\n\n \n020 7418 8900\n\n\n\n\nHybridan LLP (Joint Corporate Broker)\nClaire Noyce\n \n\n\n \n020 3764 2341\n\n\n\n\nICR Consilium (Financial PR)\nJessica Hodgson / Davide Salvi / Kumail Waljee\n\n\n \n0203 709 5700\n\n\n\n\n \nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of United Kingdom ...